To determine the effect of additional inhibition of the PI3K/AKT/mTOR pathway on further suppression of tumor growth, we treated MDAH2774 and SKOV3 ovarian cancer cells with a combination of sunitinib and dasatinib, either with or without an AKT inhibitor (MK-2206) or an mTOR inhibitor (everolimus) at various concentrations at a fixed molar ratio, then measured cell viability. Here, AKT1 is linked to ovarian cancer.